MorphoSys and Galapagos Enter Alliance to Co-develop Novel Therapeutic Antibodies in Bone and Joint Disease (28 Nov 2008) Combination of Proprietary Drug Targets and Unique Technologies to Create Range of New Therapeutic Antibodies on novel modes of action in bone and joint disease, including rheumatoid arthritis... in bone and joint disease in addition to its adenoviral target discovery platform.... An initial set of three targets implicated in bone and joint disease has been selected...
EMEA grants Kiadis Pharma lead product ATIR orphan drug designation (24 Sep 2008) of acute Graft versus Host Disease (GvHD) following an allogeneic bone marrow... mismatched bone marrow transplantation as a treatment option for end-stage blood... life-threatening GvHD, a major complication of allogeneic bone marrow...
Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin (01 Sep 2008) Results Further Support the Clinical Profile of This Novel Anti-Cancer in patients with painful bone metastases could produce increasing clinical..., no significant bone marrow toxicity was observed. The BC1-03 study was a double-blind... of Alpharadin was measured using an assessment of bone pain as well...
Hydrogels provide scaffolding for growth of bone cells (19 Aug 2008) provide a suitable scaffolding to enable bone regeneration. The hydrogels... and development of bone. Currently, physicians are able to treat patients with damaged bone tissue, like those who have bone fractures that fail to heal, using...
Top